Profile data is unavailable for this security.
About the company
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
- Revenue in USD (TTM)30.91m
- Net income in USD-88.74m
- Incorporated2016
- Employees124.00
- LocationMetagenomi Inc5959 Horton St, Floor 7EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 871-4880
- Fax+1 (302) 636-5454
- Websitehttps://metagenomi.co/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 50.58m | 2.00 | -- | -- | -- | 208.99 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 50.72m | 21.00 | -- | 7.17 | -- | 9.65 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 51.43m | 75.00 | -- | 0.3999 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.82m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 52.89m | 146.00 | -- | 0.3672 | -- | 6.28 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Estrella Immunopharma Inc | 0.00 | -13.50m | 53.17m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Beyondspring Inc | 0.00 | -7.83m | 53.24m | 40.00 | -- | -- | -- | -- | -0.1942 | -0.0148 | 0.00 | -0.788 | -- | -- | -- | 0.00 | -- | -61.84 | -- | -81.30 | -- | -- | -- | -6,633.90 | -- | -- | -- | -- | -- | -- | 35.26 | -- | 123.69 | -- |
| Kazia Therapeutics Ltd (ADR) | 80.59k | -14.63m | 53.74m | 12.00 | -- | -- | -- | 666.84 | -12.28 | -12.28 | 0.0561 | -3.62 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -75.08m | 54.19m | 14.00 | -- | 0.45 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Metagenomi Therapeutics Inc | 30.91m | -88.74m | 54.80m | 124.00 | -- | 0.3072 | -- | 1.77 | -2.39 | -2.39 | 0.8308 | 4.75 | 0.102 | -- | 39.91 | 153,034.70 | -29.27 | -- | -33.42 | -- | -- | -- | -287.06 | -- | -- | -- | 0.00 | -- | 16.84 | -- | -14.36 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -5.98m | 55.86m | 32.00 | -- | 0.8608 | -- | -- | -0.3607 | -0.3607 | 0.00 | 4.19 | 0.00 | -- | -- | -- | -9.22 | -24.13 | -9.46 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 56.40m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 59.06m | 63.00 | -- | 0.4861 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.67m | 59.54m | 0.00 | -- | -- | -- | -- | -0.1455 | -0.1455 | 0.00 | -0.1168 | 0.00 | -- | -- | -- | -5,576.42 | -14,417.91 | -- | -- | -- | -- | -- | -- | -- | -684.26 | -- | -- | -- | -- | -106.65 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Metagenomi Inc's reporting currency: US Dollar USD
11.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.09m | 2.89% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 628.40k | 1.67% |
| Catalio Capital Management LP (Investment Management)as of 30 Sep 2025 | 528.99k | 1.41% |
| Peapod Lane Capital LLCas of 31 Dec 2025 | 497.65k | 1.33% |
| Jane Street Capital LLCas of 31 Dec 2025 | 433.86k | 1.16% |
| Millennium Management LLCas of 30 Sep 2025 | 310.69k | 0.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 305.91k | 0.82% |
| Pura Vida Investments LLCas of 31 Dec 2025 | 264.39k | 0.70% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 218.94k | 0.58% |
| Two Sigma Investments LPas of 30 Sep 2025 | 207.53k | 0.55% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
